Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E23.02 EPS (ttm)5.91 Insider Own0.05% Shs Outstand2.69B Perf Week2.00%
Market Cap366.42B Forward P/E17.58 EPS next Y7.75 Insider Trans-12.77% Shs Float2.68B Perf Month1.24%
Income16.34B PEG3.63 EPS next Q1.80 Inst Own67.90% Short Float0.52% Perf Quarter1.23%
Sales72.53B P/S5.05 EPS this Y8.30% Inst Trans-0.02% Short Ratio2.64 Perf Half Y11.74%
Book/sh26.72 P/B5.09 EPS next Y7.84% ROA11.30% Target Price138.65 Perf Year15.79%
Cash/sh4.77 P/C28.51 EPS next 5Y6.34% ROE22.90% 52W Range109.32 - 137.52 Perf YTD18.15%
Dividend3.36 P/FCF41.49 EPS past 5Y11.20% ROI17.00% 52W High-1.02% Beta0.80
Dividend %2.47% Quick Ratio1.00 Sales past 5Y2.00% Gross Margin69.40% 52W Low24.52% ATR1.53
Employees126400 Current Ratio1.30 Sales Q/Q1.90% Oper. Margin27.50% RSI (14)63.51 Volatility1.22% 1.03%
OptionableYes Debt/Eq0.48 EPS Q/Q-2.40% Profit Margin22.50% Rel Volume0.98 Prev Close136.43
ShortableYes LT Debt/Eq0.38 EarningsOct 17 BMO Payout53.80% Avg Volume5.25M Price136.12
Recom2.50 SMA202.42% SMA502.54% SMA2007.33% Volume5,118,029 Change-0.23%
Oct-16-17Reiterated Jefferies Buy $157 → $160
Oct-11-17Upgrade Jefferies Hold → Buy
Oct-09-17Upgrade Wells Fargo Market Perform → Outperform
Sep-25-17Initiated Citigroup Neutral $140
Sep-20-17Downgrade Goldman Neutral → Sell $125 → $130
Jul-21-17Downgrade BTIG Research Neutral → Sell $110
Jul-21-17Downgrade Alembic Global Advisors Neutral → Underweight
Jul-20-17Resumed Credit Suisse Outperform $148
Jul-05-17Reiterated Morgan Stanley Overweight $135 → $140
May-18-17Reiterated Stifel Hold $124 → $128
May-15-17Upgrade JP Morgan Neutral → Overweight
Jan-26-17Downgrade Wells Fargo Outperform → Market Perform
Jan-25-17Reiterated RBC Capital Mkts Outperform $133 → $128
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Oct-16-17 06:33PM  5 Earnings All Stars to Start Off the Week Zacks
04:28PM  Impact of FASB's Pension Cost Accounting Rule Change Forbes
04:25PM  Johnson & Johnson earnings: All eyes on hurricane impact MarketWatch
12:29PM  Why Johnson & Johnson's Stock Could Rise 10% Investopedia
10:40AM  Johnson & Johnsons 3Q17 Estimates: Pharmaceuticals Segment Market Realist
10:40AM  Vaccines Business Expected to Boost Sanofis Revenues in 2017 Market Realist
10:38AM  How Johnson & Johnsons Recent Launches Could Affect 3Q17 Earnings Market Realist
09:38AM  J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use Zacks
09:10AM  Johnson & Johnsons 3Q17 Revenue Estimates Could Reveal Growth Market Realist
09:07AM  Will JNJs Medical Device Segment Momentum Continue in 3Q17? Market Realist
07:42AM  What to Expect from Johnson & Johnsons 3Q17 Earnings Market Realist
07:40AM  J&J Unit Sued Over 'Defective' Hip Implants in U.K. Trial Bloomberg
07:39AM  3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report Motley Fool
07:38AM  Why Wall Street Is Bullish on JNJ Stock ahead of 3Q17 Results Market Realist
Oct-15-17 12:36PM  [$$] China party congress, third-quarter results, Japan votes Financial Times
Oct-14-17 12:10AM  Earnings Season Preview: 2 Things to Watch For in Healthcare Motley Fool
Oct-13-17 06:52PM  HP Inc. CEO: 3-D printing & the inevitable manufacturing ... CNBC Videos
06:41PM  HP Inc. CEO: We got into 3-D printing to get ahead of the... CNBC Videos
06:22PM  HP Inc. CEO: We got into 3-D printing to get ahead of the inevitable manufacturing disruption CNBC
05:03PM  J&J psoriasis drug gets expanded U.S. approval for teens Reuters
01:40PM  What Factors Will Drive Johnson & Johnson's Q3 Earnings? Forbes
11:42AM  Behind Eli Lillys October Analyst Recommendations Market Realist
11:19AM  JNJ And IBM Report Q3 Earnings Early Next Week: What Might Be In Store? Benzinga
10:47AM  Pharma Sales Could Be Chilled by Hurricane Damage Barrons.com
09:45AM  Fundamental Equity Analysis Consolidated Research on Johnson & Johnson, Home Depot, Adobe, Disney, AbbVie, and eBay Developing Opportunities, Future Expectations, and Projections GlobeNewswire
01:35AM  2 Reasons Pfizer Is on Our Minds Today Motley Fool
12:50AM  [$$] Outcome, a Hot Tech Startup, Misled Advertisers With Manipulated Information, Sources Say The Wall Street Journal
Oct-12-17 08:09PM  [$$] Outcome, a Hot Tech Startup, Misled Advertisers With Manipulated Information, Sources Say The Wall Street Journal
06:34PM  MedTech Players Eyeing Emerging Market Growth Opportunities Zacks
06:32PM  Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn CNBC
04:28PM  Dow's J&J Flirts With Buy Point On Bullish Pre-Earnings Report Investor's Business Daily
12:43PM  Johnson & Johnson: Another Day, Another Bullish Analyst Barrons.com
10:50AM  J&J (JNJ) to Kickstart Pharma Q3 Earnings: What's in Store? Zacks
09:57AM  Stock Market News For Oct 12, 2017 Zacks
08:00AM  Trending: Oil Rises as Supply Glut Fears Abate ETF Database
07:33AM  3 Stocks Retirees Should Buy on a Market Pullback Motley Fool
05:00AM  J&J Blames Jury Misconduct for $417 Million Talc Verdict Bloomberg
01:02AM  Asian shares mostly rise, taking cue from Wall Street gains Associated Press
Oct-11-17 07:33PM  Can Johnson & Johnson Really Start Growing Again? Motley Fool
04:52PM  US STOCKS-Wall St ticks higher to record close; eyes on earnings, Fed Reuters
04:15PM  Stocks Strengthen At Close; Wal-Mart, Alphabet Stir The Advance Investor's Business Daily
03:41PM  US STOCKS-Wall St ticks higher with eyes on earnings Reuters
02:33PM  Is Johnson & Johnson the Best Dividend Stock in Healthcare? Motley Fool
02:18PM  This Dow component getting more love & other top movers CNBC Videos
01:30PM  Pharma business is key to Johnson & Johnson: Jefferies an... CNBC Videos
01:09PM  IQ100 index beating market by 25% CNBC Videos
01:07PM  US STOCKS-Dow inches up to record-high on gains in J&J, Wal-Mart Reuters
10:22AM  Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit Zacks
10:20AM  Stocks Trade Mixed; Retailers Struggle, J&J Nears Breakout Investor's Business Daily
09:39AM  Stocks Flat At Open; Delta Tops Views, MoviePass Parent Spikes Investor's Business Daily
08:40AM  J&J gets second upgrade this week as Jefferies calls it a 'dividend machine' CNBC
08:04AM  3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff Motley Fool
Oct-10-17 01:30PM  Healthcare: Are These the Best Dividend Stocks to Buy Now? Motley Fool
12:16PM  Johnson & Johnson Shares May Need a Band-Aid Before They Can Rally TheStreet.com
09:37AM  Will Dow ETFs Continue to Shine in Q3 Earnings? Zacks
09:03AM  5 Rules Digital Marketers at J&J, SoFi, J.P. Morgan, and IBM Swear By Fortune
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
06:04AM  3 Healthcare Dividend Stocks Ideal for Retirees Motley Fool
Oct-09-17 11:51PM  Buy J&J on Q3 Turning Point': Wells Fargo Investopedia
04:30PM  2 Stocks Your Children Will Brag About Someday Motley Fool
03:49PM  Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September Motley Fool
10:18AM  Deloitte Is Dramatically Moving the Conversation from Diversity to Inclusion TheStreet.com
09:44AM  Dow, Nasdaq Take New Highs; GE Down After Shake-Up Investor's Business Daily
08:54AM  Morning Movers: Honeywell Rises on Split Plans; Viacom Tumbles Barrons.com
08:52AM  J&J shares upgraded by Wells Fargo, which says the third quarter was 'turning point' for stock CNBC
07:44AM  Analysts Recommendations for Amgen in October 2017 Market Realist
Oct-08-17 08:08AM  3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now Motley Fool
Oct-07-17 10:43AM  3 Blockbuster Drugs That Still Cost More Than They Should Motley Fool
Oct-06-17 04:10PM  Here's What's Has Happened in the HCV Space Lately Zacks
02:02PM  Is Johnson & Johnson Sitting Out the Rally? TheStreet.com
11:38AM  Gilead Sciences & AbbVie: Mother Always Told Me to Share Barrons.com
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
04:48AM  Awaiting better days, multinationals keep Venezuela units alive - barely Reuters
01:44AM  Bayer says Phase III Xarelto study halted early Reuters
01:07AM  Insight: Awaiting better days, multinationals keep Venezuela units alive - barely Reuters
01:07AM  Awaiting better days, multinationals keep Venezuela units alive - barely Reuters
Oct-05-17 08:05PM  How Johnson & Johnson (JNJ) Delivered A Better ROE Than Its Industry Simply Wall St.
04:37PM  4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3 Zacks
11:52AM  Johnson & Johnson Calls It Quits on Insulin Pumps Business TheStreet.com
11:50AM  Chesco insulin pump maker closing. It impacts 400 employees, 90K diabetics. American City Business Journals
10:43AM  J&J unit exits insulin pump business amid rising competition Reuters
08:27AM  J&J's diabetes care unit to exit insulin pump business Reuters
08:12AM  [$$] J&J Abandoning Insulin Pumps The Wall Street Journal
08:11AM  Johnson & Johnson breached its 50 day moving average in a Bullish Manner : JNJ-US : October 5, 2017 Capital Cube
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
07:12AM  Johnson & Johnson's Animas to close operations, exit the insulin pump business MarketWatch
04:00AM  The Lawyer Who Beat Big Tobacco Takes On the Opioid Industry Bloomberg
Oct-04-17 01:00PM  Why Microsoft Corporation (MSFT) Stock Can Give You the Upper Hand InvestorPlace
11:51AM  [$$] 6 Top Pharma Picks for Q4 Barrons.com
09:45AM  6 Pharma Stocks to Buy Now Barrons.com
08:00AM  The Hepatitis Drug Market Is Worse Than Wall Street Realizes Bloomberg
08:00AM  See what the IHS Markit Score report has to say about Johnson & Johnson. Markit
Oct-03-17 02:20PM  Here's When to Go Long Johnson & Johnson TheStreet.com
10:59AM  Johnson & Johnson Files sNDA for Label Expansion of Invokana Zacks
10:39AM  Is This How Drugmakers Will Kill Biosimilars? Motley Fool
10:24AM  Integra Closes Codman Buyout, Strengthens Neurosurgery Arm Zacks
09:24AM  Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs? Zacks
08:14AM  The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO Zacks
06:00AM  The Impact of Tax Reform On Stock Prices Morningstar
Oct-02-17 06:06PM  Abbotts Breakthrough CGM Device Freestyle Libre Wins FDA Approval Market Realist
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoffels PaulusExec VP, Chief Scientific OffJul 24Option Exercise72.54102,6927,449,278230,342Jul 26 11:49 AM
Stoffels PaulusExec VP, Chief Scientific OffJul 24Sale133.14102,69213,672,629127,650Jul 26 11:49 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Option Exercise61.7582,5915,099,994226,693Jul 24 11:06 AM
Caruso Dominic JExec VP, Finance; CFOJul 20Sale136.7282,59111,291,478144,102Jul 24 11:06 AM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Option Exercise59.7650,0002,987,780118,536Mar 07 04:21 PM
Duato JoaquinExec VP, WW Chair, PharmaMar 03Sale123.6250,0006,181,14068,536Mar 07 04:21 PM
Kapusta Ronald AController, CAOFeb 28Option Exercise72.5414,5431,054,94944,507Mar 02 05:50 PM
Kapusta Ronald AController, CAOFeb 28Sale122.2614,5431,777,95429,964Mar 02 05:50 PM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 28Sale122.2116,2991,991,94343,630Mar 02 05:16 PM
Stoffels PaulusExec VP, Chief Scientific OffFeb 15Sale117.2922,0002,580,274127,650Feb 16 06:53 PM
Caruso Dominic JExec VP, Finance; CFOFeb 13Option Exercise0.0026,9470150,700Feb 15 10:00 PM
Kapusta Ronald AController, CAOFeb 13Option Exercise0.002,148030,052Feb 16 06:01 AM
Pruden Gary JExec VP, WW Chair, Med DevicesFeb 13Option Exercise0.0015,532063,405Feb 16 06:01 AM
Duato JoaquinExec VP, WW Chair, PharmaFeb 13Option Exercise0.0022,298075,814Feb 16 06:01 AM
Fasolo PeterExec VP, Chief HR OfficerFeb 13Option Exercise0.0015,598068,899Feb 16 06:01 AM
Gorsky AlexChairman, CEOFeb 13Option Exercise0.0084,2990280,617Feb 16 06:01 AM
PETERSON SANDRA EExec VP, Group WW ChairmanFeb 13Option Exercise0.0027,667069,436Feb 16 06:01 AM
Stoffels PaulusExec VP, Chief Scientific OffFeb 13Option Exercise0.0026,4470156,125Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 13Option Exercise0.0014,6000114,866Feb 16 06:01 AM
Ullmann Michael HExec VP, General CounselFeb 01Option Exercise65.6227,7351,819,971119,190Feb 03 12:05 PM
Ullmann Michael HExec VP, General CounselFeb 01Sale112.8821,7352,453,44297,455Feb 03 12:05 PM
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM